Join
Live feed
·
PRReleasevia Quantisnow
Lixte Biotechnology Holdings Inc. logo

LIXTE Biotechnology Announces $16,566,027 Registered Direct Offering Priced at the Market Under Nasdaq Rules, Strengthening Balance Sheet for Next Phase of Strategic Growth

ByQuantisnow·Wall Street's wire, on your screen.
LIXT· Lixte Biotechnology Holdings Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track LIXT (Lixte Biotechnology Holdings Inc.) and more on Quantisnow.